Five Prime Therapeutics Inc (NASDAQ:FPRX) – Research analysts at Svb Leerink upped their FY2019 earnings per share (EPS) estimates for Five Prime Therapeutics in a note issued to investors on Wednesday, November 6th. Svb Leerink analyst J. Chang now expects that the biotechnology company will earn ($4.23) per share for the year, up from their prior estimate of ($4.27). Svb Leerink also issued estimates for Five Prime Therapeutics’ Q4 2019 earnings at ($1.19) EPS and FY2020 earnings at ($3.06) EPS.
Five Prime Therapeutics (NASDAQ:FPRX) last issued its quarterly earnings results on Wednesday, November 6th. The biotechnology company reported ($1.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.08). Five Prime Therapeutics had a negative net margin of 921.30% and a negative return on equity of 65.39%. The firm had revenue of $2.98 million for the quarter, compared to analysts’ expectations of $4.33 million.
Shares of NASDAQ FPRX opened at $3.91 on Monday. Five Prime Therapeutics has a one year low of $3.22 and a one year high of $13.97. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.93 and a quick ratio of 6.93. The business’s fifty day moving average price is $4.06 and its 200-day moving average price is $6.15. The stock has a market capitalization of $141.56 million, a PE ratio of -0.95 and a beta of 2.55.
In related news, major shareholder Bvf Partners L. P/Il acquired 6,833 shares of the company’s stock in a transaction that occurred on Thursday, October 31st. The shares were acquired at an average price of $3.85 per share, with a total value of $26,307.05. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, major shareholder Bvf Partners L. P/Il acquired 968,112 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The shares were bought at an average cost of $4.00 per share, for a total transaction of $3,872,448.00. The disclosure for this purchase can be found here. Insiders have purchased a total of 2,352,563 shares of company stock worth $9,131,479 in the last three months. 7.10% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the business. Renaissance Technologies LLC increased its stake in Five Prime Therapeutics by 86.5% in the 2nd quarter. Renaissance Technologies LLC now owns 1,149,200 shares of the biotechnology company’s stock worth $6,930,000 after acquiring an additional 533,100 shares during the last quarter. Man Group plc increased its stake in Five Prime Therapeutics by 95.9% in the 2nd quarter. Man Group plc now owns 1,160,411 shares of the biotechnology company’s stock worth $6,997,000 after acquiring an additional 568,017 shares during the last quarter. Morgan Stanley increased its stake in Five Prime Therapeutics by 1,167.3% in the 2nd quarter. Morgan Stanley now owns 258,317 shares of the biotechnology company’s stock worth $1,558,000 after acquiring an additional 237,933 shares during the last quarter. JPMorgan Chase & Co. increased its position in shares of Five Prime Therapeutics by 32.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 321,907 shares of the biotechnology company’s stock valued at $1,947,000 after purchasing an additional 78,404 shares during the last quarter. Finally, Panagora Asset Management Inc. increased its position in shares of Five Prime Therapeutics by 1,229.5% during the 2nd quarter. Panagora Asset Management Inc. now owns 183,933 shares of the biotechnology company’s stock valued at $1,109,000 after purchasing an additional 170,098 shares during the last quarter. Institutional investors and hedge funds own 74.41% of the company’s stock.
Five Prime Therapeutics Company Profile
Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase III clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that targets B7-H4 in various cancers, as well as FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28.
Featured Article: Bear Market – How and Why They Occur
Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.